Hubbry Logo
Cutter LaboratoriesCutter LaboratoriesMain
Open search
Cutter Laboratories
Community hub
Cutter Laboratories
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cutter Laboratories
Cutter Laboratories
Cutter Laboratories
View on Wikipedia
from Wikipedia

Cutter Laboratories was a family-owned pharmaceutical company located in Berkeley, California, founded by Edward Ahern Cutter in 1897. Cutter's early products included anthrax vaccine, hog cholera (swine fever) virus, and anti-hog cholera serum—and eventually a hog cholera vaccine. The hog cholera vaccine was the first tissue culture vaccine, human or veterinary, ever produced. The company expanded considerably during World War II as a consequence of government contracts for blood plasma and penicillin. After Edward Cutter's death, his three sons—Robert K. Cutter (president), Edward "Ted" A. Cutter Jr. (vice-president), and Frederick A. Cutter—ran the company. In the next generation Robert's son David followed his father as president of the company. The Bayer pharmaceutical company bought Cutter Laboratories in 1974.[1]

Cutter incident

[edit]

On April 12, 1955, following the announcement of the success of the polio vaccine trial, Cutter Laboratories became one of several companies that was recommended to be given a license by the United States government to produce Jonas Salk's polio vaccine. In anticipation of the demand for vaccine, the companies had already produced stocks of the vaccine and these were issued once the licenses were signed.

In what became known as the Cutter incident, some lots of the Cutter vaccine—despite passing required safety tests—contained live polio virus in what was supposed to be an inactivated-virus vaccine. Cutter withdrew its vaccine from the market on April 27 after vaccine-associated cases were reported.

The mistake produced 120,000 doses of polio vaccine that contained live polio virus. Of children who received the vaccine, 40,000 developed abortive poliomyelitis (a form of the disease that does not involve the central nervous system), 56 developed paralytic poliomyelitis—and of these, five children died from polio.[2] The exposures led to an epidemic of polio in the families and communities of the affected children, resulting in a further 113 people paralyzed and 5 deaths.[3] The director of the microbiology institute lost his job, as did the equivalent of the assistant secretary for health. Secretary of Health, Education, and Welfare Oveta Culp Hobby stepped down. William H. Sebrell Jr, the director of the NIH, resigned.[4]

Surgeon General Scheele sent William Tripp and Karl Habel from the NIH to inspect Cutter's Berkeley facilities, question workers, and examine records. After a thorough investigation, they found nothing wrong with Cutter's production methods.[5] A congressional hearing in June 1955 concluded that the problem was primarily the lack of scrutiny from the NIH Laboratory of Biologics Control (and its excessive trust in the National Foundation for Infantile Paralysis reports).[4]

A number of civil lawsuits were filed against Cutter Laboratories in subsequent years, the first of which was Gottsdanker v. Cutter Laboratories.[6] The jury found Cutter not negligent, but liable for breach of implied warranty, and awarded the plaintiffs monetary damages. This set a precedent for later lawsuits. All five companies that produced the Salk vaccine in 1955—Eli Lilly, Parke-Davis, Wyeth, Pitman-Moore, and Cutter—had difficulty completely inactivating the polio virus. Three companies other than Cutter were sued, but the cases settled out of court.[7]

The Cutter incident was one of the worst pharmaceutical disasters in US history, and exposed several thousand children to live polio virus on vaccination.[3] The NIH Laboratory of Biologics Control, which had certified the Cutter polio vaccine, had received advance warnings of problems: in 1954, staff member Bernice Eddy had reported to her superiors that some inoculated monkeys had become paralyzed and provided photographs. William Sebrell, the director of NIH, rejected the report.[4][clarification needed]

Expansion

[edit]

Despite lawsuits resulting from vaccine-related cases of polio, Cutter Laboratories successfully expanded its business. Between 1955 and 1960, they purchased:

  • Veterinary product manufacturers Ashe-Lockhart, Inc. and Haver-Glover Laboratories of Kansas City
  • Plastic manufacturers Plastron Specialties, Pacific Plastics Company in San Francisco, and Olympic Plastics Company in Los Angeles
  • An animal feed farm, Corn King Company, in Cedar Rapids
  • A plant-derived allergy medicine company, Hollister-Stier, in Spokane, Los Angeles, Philadelphia, and Atlanta

In 1960, Cutter established Cutter Laboratories Pacific, Inc. in Japan. Annual Cutter company sales had increased from $11,482,000 in 1955 to $29,934,000 in 1962. In the early 1960s, Cutter's catalog listed more than 700 products, and in 1962, the company's assets were "80% greater than when the polio disaster had occurred."[8] Cutter Laboratories was purchased by the German chemical and pharmaceutical company Bayer in 1974.[1]

Other incidents

[edit]

In the late 1970s through 1980s, numerous companies, including Bayer's Cutter Biologic division, produced unsafe blood products (specifically factor VIII) to treat hemophilia. The pharmaceutical product, produced from blood from donors across the US, was contaminated with the HIV virus at a time when HIV could not be screened out. These problems led to lawsuits over the next 20 years.[9]

A 2008 German documentary called Tödlicher Ausverkauf: Wie BAYER AIDS nach Asien importierte (Deadly Sale: How Bayer imported AIDS into Asia)[10] researched the Koate product for hemophiliacs sold by Bayer's Cutter division under full knowledge of its HIV contamination.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cutter Laboratories

View on Grokipedia
from Grokipedia
Cutter Laboratories was an American pharmaceutical and biologics manufacturer founded in 1897 by Edward Ahern Cutter in , initially as a bacteriological for clinical sample analysis and later expanding into production of vaccines, antitoxins, and plasma-derived products. The company operated as a family-owned firm with facilities in Berkeley and other sites, supplying biologicals for needs including early and vaccines, and by the mid-20th century, it participated in the national effort to produce Jonas Salk's inactivated following successful field trials. Its most consequential event, the 1955 Cutter Incident, arose when several batches of its polio vaccine contained live virus due to inadequate inactivation processes and flawed safety testing, infecting over 200,000 individuals, causing approximately 40,000 polio cases, paralyzing about 200 children, and resulting in at least 10 deaths. This failure, despite federal licensing, exposed deficiencies in manufacturing oversight and led to immediate suspension of vaccination campaigns, congressional investigations, and the establishment of stricter regulatory frameworks, including the Division of Biologics Standards within the to enforce safety protocols. While Cutter Laboratories resumed some operations and was acquired by in the before further corporate integrations, the incident underscored causal risks in biological production—such as incomplete neutralization—and remains a pivotal in safety and liability precedents.

Founding and Early History

Establishment and Initial Operations

Cutter Laboratories was established in 1897 by Ahern Cutter in , initially as a bacteriological dedicated to the analysis of clinical samples. This founding reflected the era's growing demand for diagnostic services amid advances in , with operations centered on testing rather than large-scale manufacturing. Early activities quickly extended beyond diagnostics to the production of veterinary biologics, including vaccines against and blackleg (Clostridium chauvoei infections) in , as well as hog cholera serum. These products addressed prevalent diseases, establishing the company's foothold in biologicals through empirical testing and formulation processes typical of nascent pharmaceutical ventures. The firm's initial scale remained modest, operating as a family-owned entity with a focus on quality-controlled production informed by direct bacteriological expertise, prior to expansions that would follow relocation.

Relocation and Pre-WWII Growth

In 1897, Edward Ahern Cutter established Cutter Analytic Laboratories in , initially as a pharmaceutical and analytic firm focused on basic chemical and biological preparations. In 1903, the company relocated to , where it purchased a block in West Berkeley for expanded production and research facilities, adopting the name Cutter Laboratories and beginning commercial production of vaccines and antitoxin. This move positioned the firm amid Berkeley's emerging industrial corridor, leveraging proximity to the for scientific talent while capitalizing on California's agricultural resources for animal-derived biologics. Pre-World War II growth centered on veterinary biologics, with Cutter producing vaccines for diseases such as hog cholera, , and blackleg, utilizing guinea pigs, horses, and cattle in testing and generation. By the , the company diversified into human pharmaceuticals, developing and antitoxins through large-scale animal immunization processes, which required herds of horses maintained at dedicated stables. This expansion reflected rising demand for serum therapies amid early 20th-century campaigns, enabling Cutter to scale output from its Berkeley plants while adhering to nascent federal licensing standards under the 1902 Biologics Control Act. Further infrastructure development occurred in the 1930s, including the acquisition of a ranch in El Sobrante (along present-day Castro Ranch Road) by 1936 to house animals for vaccine production and safety testing, addressing space constraints in urban Berkeley and supporting rigorous potency assays. Under family leadership, including Edward Cutter's oversight, the firm grew into a mid-sized biologics manufacturer, employing dozens in specialized roles like serum fractionation and sterility control, though it remained smaller than East Coast competitors due to its Western focus on animal health derivatives. This period solidified Cutter's reputation for reliable, if niche, vaccine and antitoxin supply chains, setting the stage for wartime contracts.

Products and Innovations

Veterinary Vaccines and Firsts

Cutter Laboratories, established in , initially focused on biological products for veterinary use, capitalizing on the demand for vaccines and serums to combat livestock diseases that threatened agricultural economies. By 1903, after relocating production facilities to , the company expanded its output to include vaccines for and other animals, as well as serums addressing prevalent infections like hog cholera (swine fever). These early efforts positioned Cutter as a leader in veterinary biologics, with products such as anti-hog cholera serum and preparations that facilitated simultaneous and treatment protocols. A key innovation came in the development of Cutter's hog cholera , recognized as the first ever produced for human or veterinary applications. This breakthrough, leveraging techniques for propagation, improved production efficiency and purity compared to earlier embryonated egg or animal tissue methods, influencing subsequent vaccine manufacturing standards. The company also manufactured blackleg bacterin (Blacklegol), a killed broth culture targeting the chauvoei bacterium responsible for the acute muscle infection in , with pill-form variants noted in production by 1908. Cutter extended its veterinary portfolio to companion animals, producing anti-canine distemper serum using homologous methods derived from recovered canine sources, as well as anti-mixed serums for preventing secondary bacterial complications in dogs during the 1930s and 1940s. Additionally, the firm developed vaccines for equine and other pathogens affecting horses, contributing to broader advancements in animal health prior to its pivot toward human pharmaceuticals during . These veterinary "firsts" and staples underscored Cutter's role in reducing economic losses from epizootics, though production relied on rigorous protocols involving guinea pigs and other species at dedicated facilities.

Human Pharmaceuticals and Other Lines

Cutter Laboratories began diversifying into human pharmaceuticals in the , transitioning from its veterinary focus by applying expertise in animal-derived biologics to develop treatments for human use, including early sera and antitoxins tested via animal models. The company's production capacity expanded markedly during through U.S. government contracts, manufacturing for transfusion therapy to address hemorrhagic shock in combat casualties and penicillin as a critical for treating bacterial infections in wounded soldiers. Beyond antibiotics and plasma, Cutter produced human biologics such as tetanus immune globulin, derived from hyperimmunized human donors to provide against tetanus toxin, and plague vaccine, a killed-bacteria formulation licensed for preventing in at-risk populations. These products reflected Cutter's emphasis on biological manufacturing processes, including of plasma and inactivation of pathogens, though limitations in such methods later drew scrutiny in unrelated incidents.

Involvement in Polio Vaccine Development

Context of 1950s Polio Eradication Efforts

In the early , poliomyelitis epidemics reached devastating peaks , with an average of 16,316 paralytic cases and 1,879 deaths reported annually from 1951 to 1954, culminating in over 21,000 paralytic cases in 1952 alone. The disease, caused by strains transmitted primarily through fecal-oral routes, inflicted widespread paralysis, respiratory failure, and death, particularly among children, prompting school closures, public pool shutdowns, and pervasive societal fear during annual summer outbreaks. These epidemics underscored the urgency for a preventive measure, as no effective treatment existed beyond supportive care like iron lungs for severe cases. The National Foundation for Infantile Paralysis (NFIP), later known for its "March of Dimes" fundraising campaigns initiated in 1938 by President —a polio survivor—mobilized public donations exceeding $230 million by the mid-1950s to fund polio research, patient care, and rehabilitation. This private supported virological breakthroughs, including the 1949 cultivation of in non-nerve tissue by John Enders, Thomas Weller, and Frederick Robbins, enabling development, and directly financed Jonas Salk's work at the starting in 1948. Salk's team pursued an inactivated (killed-virus) , conducting initial human trials on children in 1953 after demonstrating safety and in animal models and limited volunteer tests. To validate efficacy, the NFIP orchestrated the largest in history in , involving approximately 1.8 million children across the U.S. in a double-blind, placebo-controlled study overseen by Thomas Francis Jr. at the University of Michigan's Vaccine Evaluation Center. Preliminary results from observed and controlled cohorts showed the to be 60-90% effective against paralytic , with Francis announcing on April 12, 1955, that it was "safe, effective, and potent." The U.S. Public Health Service licensed the Salk that same day, initiating a national campaign with production scaled up by five manufacturers to vaccinate schoolchildren en masse, aiming for rapid and eventual eradication.

Manufacturing Process for Salk Vaccine

Cutter Laboratories employed the standardized protocol developed by for producing inactivated vaccine (IPV), licensed by the U.S. government on April 12, 1955, as one of five authorized manufacturers. The process began with propagation of the three serotypes—Type 1 (Mahoney strain), Type 2 (MEF-1 strain), and Type 3 (Saukett strain)—in primary monolayer cultures derived from rhesus monkey kidneys. Kidneys were harvested from imported rhesus monkeys euthanized for this purpose, minced, and treated with to dissociate cells into suspensions, which were then seeded into glass vessels such as roller bottles containing nutrient medium (typically including lactalbumin hydrolysate, , and calf serum buffered to physiological pH). Once confluent, cultures were infected with low-passage seed virus stocks at a multiplicity allowing maximal yield, followed by incubation at 35–37°C for 4–7 days until cytopathic effects indicated high viral titers, often exceeding 10^8–10^9 TCID50/ml. Harvested virus fluids were clarified by low-speed or to remove cellular debris, yielding monovalent bulk harvests. Inactivation, the critical step to render the non-infectious while retaining antigenicity, involved adding neutral formalin (37–40% in water) to achieve a final concentration of 0.01–0.02%, followed by incubation at 36–37°C for 10–14 days, with the exact duration adjusted based on pre-determined inactivation kinetics derived from pilot tests (e.g., longer for higher titers to ensure logarithmic kill). This relied on 's covalent binding to viral and nucleic acids, though empirical validation through periodic sampling for residual infectivity was required. Post-inactivation, excess formalin was neutralized with or thiosulfate, and the bulk was further purified if needed via adsorption or dialysis to reduce pyrogens and non-specific proteins. Monovalent components passing initial safety tests— including assays on cells for absence of live and limited for neurovirulence—were blended proportionally (typically equal parts by content) into trivalent , with 0.01% merthiolate added as . Final formulation was filled into 10-dose vials under sterile conditions, with each lot subjected to federal oversight including potency assays (measuring response in pigs or monkeys) and sterility checks. Unlike laboratory-scale production at Salk's facility, Cutter's commercial scaling introduced challenges such as batch-to-batch variability in quality and inactivation uniformity, exacerbated by the company's relative inexperience in large-scale compared to competitors like . Process controls mandated sampling at multiple stages, but reliance on endpoint inactivation calculations rather than real-time molecular verification left margins for error, as formaldehyde penetration could be impeded by viral aggregates or tissue remnants.

The 1955 Cutter Incident

Vaccine Release and Initial Cases

Following the announcement of the Salk inactivated polio vaccine's efficacy on April 12, 1955, U.S. licensing authorities approved production by several manufacturers, including Cutter Laboratories in . Cutter promptly initiated distribution of its vaccine lots, with initial shipments reaching vaccination sites in mid-April. Over 200,000 children in five western and midwestern states—primarily , , Washington, Utah, and —received doses from Cutter in the first week of the national rollout, as part of expedited public health campaigns to curb epidemics. The first reports of paralysis among vaccinated children emerged on April 25, 1955, when a single case was identified in a recipient of Cutter . By April 26, five additional cases were confirmed, all linked to Cutter-administered doses. These initial incidents occurred approximately 13 days after the first vaccinations, with epidemiological tracing revealing that all affected children had received from Cutter lots, while cases in recipients of other manufacturers' products remained absent at that stage. By April 27, six Cutter-associated cases had been officially noted, prompting early scrutiny of the vaccine's safety profile despite the absence of broader inactivation failures in competing batches.

Scale of Infections and Casualties

Approximately 120,000 doses from the implicated Cutter Laboratories polio vaccine lots were administered to children in the United States in late April and early May 1955, primarily in , , , and Washington. Subsequent epidemiological investigations determined that these batches contained live due to inadequate inactivation during manufacturing, leading to an estimated 40,000 infections among recipients, most presenting as abortive polio with symptoms including fever, sore throat, headache, vomiting, and muscle pain but without . Among the infected, approximately 200 children developed paralytic poliomyelitis of varying severity, with over 160 cases resulting in permanent . Paralytic cases included both direct vaccine-induced infections and secondary transmissions to unvaccinated contacts, such as siblings and parents, totaling over 250 associated paralytic polio instances across primary and secondary exposures. The incident resulted in 10 deaths attributed to polio from the contaminated vaccine, comprising children who received the shots and at least one adult via secondary spread. Official surveillance reported 11 deaths in direct association with Cutter vaccine-related poliomyelitis cases. These casualties underscored the risks of live virus persistence in supposedly inactivated preparations, prompting immediate suspension of polio vaccination nationwide on April 27, 1955, after initial reports from Idaho.

Investigations, Causes, and Systemic Factors

Following the emergence of polio cases among vaccinated children in late April 1955, U.S. Leonard Scheele ordered an immediate halt to polio vaccinations nationwide on April 27, after initial reports from and linked symptoms to Cutter Laboratories' vaccine batches. A federal investigatory panel, convened under the (NIH) and including experts from the Service, examined manufacturing records, tests, and clinical data from affected areas. The panel's findings, released in May 1955, confirmed that specific lots from Cutter—totaling approximately 120,000 doses administered to over 200,000 children across five Western states—contained live , resulting in an estimated 40,000 cases of infection, 200 instances of (primarily among primary recipients), and 10 deaths within weeks. Further analysis by the Centers for Disease Control and Prevention (CDC) precursors traced over 250 paralytic cases directly to these batches, emphasizing the vaccine's role in secondary spread to unvaccinated contacts. The root causes centered on Cutter Laboratories' failure to fully inactivate the using Jonas Salk's protocol, which required precise control of temperature, duration, and virus concentration to ensure no viable virus remained. Unlike vaccines from , , and , which adhered to the process without incident, Cutter's production involved inadequate monitoring of inactivation steps, allowing residual live type 1 to survive in final lots despite passing initial monkey kidney tissue safety tests that were insufficiently sensitive to detect low viral loads. Laboratory records showed inconsistencies in levels and exposure times, compounded by Cutter's limited prior experience in viral manufacturing—a family-owned firm primarily known for veterinary and pharmaceutical products—which evaded detection during pre-licensing inspections by NIH's Division of Biologics Standards. Systemic factors included the rushed transition from Salk's 1954 field trials—successful in over 1.8 million children—to under immense public and political pressure from the National Foundation for Infantile Paralysis, which prioritized rapid deployment over exhaustive validation of multiple manufacturers' capabilities. Pre-1955 federal oversight lacked mandatory potency and safety assays for inactivated vaccines beyond basic , with licensing granted on April 12, 1955, based on abbreviated submissions rather than standardized GMP (good manufacturing practices). This regulatory gap, rooted in the absence of a centralized FDA vaccine authority (biologics fell under NIH), enabled variability across five licensed producers, amplifying risks from uneven expertise and in a high-demand environment that strained supply chains and encouraged shortcuts. The incident exposed how enthusiasm for overshadowed rigorous process validation, contributing to broader distrust and temporary program suspension until enhanced testing protocols were implemented in fall 1955.

Lawsuits and Liability Outcomes

Following the 1955 Cutter Incident, victims of vaccine-associated and their families filed numerous lawsuits against Cutter Laboratories, primarily alleging breach of warranty and in vaccine production. Many claims were resolved through out-of-court settlements, with reported totals exceeding $3 million by the late 1950s, providing monetary compensation to affected parties without admitting fault. These settlements addressed immediate financial needs for medical care and lost wages but varied case-by-case, lacking standardized criteria for causation or awards. A landmark case, Gottsdanker v. Cutter Laboratories (1960), involved two children who contracted poliomyelitis shortly after receiving Cutter's Salk vaccine, leading to consolidated actions for damages totaling $365,000 sought by the families. The jury rejected claims but found Cutter liable for breach of implied warranties of merchantability and fitness for human consumption, awarding $139,000 to the children for general damages and $8,300 to their parents for special damages, for a total of $147,300. The Court of Appeal upheld the verdict, extending the "food exception" to privity requirements—historically barring remote consumer suits against manufacturers—to vaccines and drugs, thereby imposing liability on Cutter directly to end-users despite no direct sale to plaintiffs. The Supreme Court denied review, solidifying the ruling's precedential weight. These outcomes established principles for vaccine manufacturers, holding Cutter accountable for product defects causing harm even without proven negligence or deviation from federal safety standards approved by the and . Courts reasoned that vaccines, as consumables intended for intimate bodily use, warranted an absolute guarantee of safety akin to food, shifting risk from consumers to producers best positioned to prevent failures in inactivation processes. Subsequent cases against Cutter reinforced this, contributing to broader doctrines but also deterring industry participation due to heightened financial exposure. No criminal liability was imposed, as investigations cleared intentional , focusing instead on civil remedies.

Reforms in Vaccine Licensing and Oversight

The 1955 Cutter incident prompted swift federal intervention, including a nationwide suspension of polio vaccinations announced by Surgeon General Leonard Scheele on May 8, 1955, to investigate the failures in vaccine production. Congressional hearings followed, revealing systemic deficiencies such as inadequate inactivation protocols, insufficient safety testing of vaccine lots, and lax oversight of manufacturers. In response, the Laboratory Division of the National Microbiological Institute was elevated to the Division of Biologics Standards (DBS) within the National Institutes of Health later in 1955, granting it explicit authority to regulate vaccine production through facility inspections, lot-by-lot potency and safety testing, and pre-licensing approval requirements. This marked a shift from prior reliance on manufacturer self-certification and limited state-level checks to centralized federal control under the Public Health Service Act of 1944, ensuring vaccines could not be distributed without DBS verification of freedom from live virus contaminants. Key manufacturing reforms addressed the root causes identified in Cutter's process, mandating enhanced formaldehyde inactivation procedures with extended exposure times (typically 10-14 days at controlled temperatures) and multiple confirmatory tests for residual live using sensitive methods like monkey kidney tissue cultures or animal inoculation, replacing the prior single-test reliance that had failed to detect viable virus. Potency assays were standardized to confirm antigenicity, while sterility and purity checks were expanded to exclude bacterial or viral contaminants. These protocols were applied rigorously before resuming vaccinations in the fall of 1955, with only manufacturers demonstrating compliance—such as and —receiving relicensure for their Salk vaccine lots after independent DBS review. The DBS framework established enduring precedents for oversight, requiring manufacturers to submit detailed production protocols and undergo unannounced inspections, with non-compliance grounds for revocation. This lot-release system, where each batch faced federal laboratory scrutiny before market entry, extended beyond to all biologics, reducing risks of incomplete inactivation or and restoring public confidence through transparent accountability. By 1956, case rates had plummeted under these safeguards, validating the reforms' in prioritizing empirical data over expedited licensing. The DBS operated until 1972, when its functions transferred to the Food and Drug Administration's Bureau of Biologics, perpetuating the heightened standards initiated post-Cutter.

Post-1955 Business Trajectory

Expansion and Diversification (1955-1970s)

Following the 1955 polio vaccine incident and ensuing legal challenges, Cutter Laboratories maintained its manufacturing operations and pursued business growth. The company hired Marcus Van Campen from Merrell Company in 1956 to oversee marketing and sales expansion. Annual sales for 1955 totaled $11,482,000, providing a baseline for subsequent increases amid diversification efforts. In 1958, Cutter acquired Hollister-Stier Laboratories, bolstering its capabilities in sterile injectable products and expanding production for pharmaceuticals and biologicals. By 1960, the firm established Cutter Laboratories Pacific, Inc., in to enter Asian markets and distribute its range of , antitoxins, and therapeutics. Product diversification included veterinary such as fowl-pox vaccine and , as cataloged in promotional materials around that period. These moves reduced dependence on polio-related biologics, incorporating antibiotics, insulin preparations, and plasma-derived items into its portfolio. Through the , Cutter broadened its offerings to over pharmaceuticals, emphasizing veterinary and human biologicals amid rising demand for blood fractionation and sterile . This period saw sustained revenue growth, with the company navigating regulatory scrutiny while scaling operations before its eventual acquisition in the mid-1970s.

Acquisition by Miles Laboratories and Bayer

In 1974, AG, a German multinational pharmaceutical and chemical company, acquired Cutter Laboratories Inc. for an undisclosed amount, marking a strategic expansion into the U.S. biologics and sector. This purchase integrated Cutter's operations in plasma-derived products, surgical sutures, and veterinary biologics into 's portfolio, leveraging Cutter's established facilities in , and its expertise in human and animal health products developed since its founding in 1903. Bayer further consolidated its U.S. presence by acquiring Miles Laboratories Inc. in 1978 for approximately $253 million, gaining control of Miles' consumer health brands such as , One-A-Day vitamins, and Bactine antiseptics, alongside Miles Canada. At the time, Miles reported annual sales of about $450 million, reflecting its growth from a small aspirin producer founded in 1884 into a diversified ethical and over-the-counter firm. The acquisition faced initial regulatory scrutiny due to concerns but was approved, positioning Bayer to compete more effectively in the American consumer and pharmaceutical markets. By 1984, restructured its subsidiaries by merging Cutter Laboratories into , effectively placing Cutter under Miles' operational umbrella while maintaining Bayer's overarching control. This integration streamlined management of overlapping product lines, including Cutter's capabilities, and aligned with Bayer's post-acquisition strategy to centralize U.S. ethical drug and biologics activities under Miles. The move followed leadership changes, with executives from Bayer's divisions assuming key roles at Miles to oversee the combined entities' expansion into diagnostics and . Under this structure, Cutter's legacy in production and plasma products continued within Miles until further corporate reorganizations in the 1990s.

Later Incidents Involving Blood Products

Factor VIII Production and HIV Risks

Cutter Laboratories, through its Cutter Biological division, manufactured antihemophilic factor (AHF) concentrates, including Factor VIII, by pooling plasma from thousands of donors—typically around 10,000 per batch—and subjecting it to a cold ethanol fractionation process to isolate the clotting proteins. This pooling amplified the risk of pathogen transmission exponentially, as contamination in even a single donor's plasma could infect the entire lot, rendering the product hazardous for hemophiliacs who required frequent intravenous infusions to manage bleeding episodes. Prior to 1985, these concentrates underwent no specific viral inactivation steps effective against HIV, nor routine donor screening for the virus, which was only conclusively identified as AIDS's causative agent in 1984. The inherent vulnerabilities in this production method became evident as early as 1981–1982, when clusters of AIDS cases emerged among hemophiliacs using commercial products, prompting investigations that linked the disease directly to the concentrates. Collaborative studies between the CDC and Cutter Laboratories in 1984 confirmed that added to concentrate retained infectivity even after standard manufacturing processes, with virus titers remaining viable at levels sufficient for transmission (up to 10^5). By February 1983, Cutter implemented donor screening in the United States following recognition of risks, but earlier batches—derived from unscreened plasma collected through high-risk practices like paid donations from prison inmates and intravenous drug users—had already disseminated the virus widely. Internal documents indicate Cutter's awareness of risks by the early , yet the company deemed the financial sunk costs in existing inventory too substantial to discard outright, prioritizing production continuity over immediate risk mitigation. Heat treatment of , developed by Cutter and other manufacturers around 1984–1985, proved effective in inactivating by denaturing the virus during at 60°C for 10 hours, reducing transmission risks dramatically once implemented. However, the transition was uneven; non-heat-treated products remained in circulation and use into 1985, contributing to ongoing infections among hemophiliacs globally, with estimates suggesting over 10,000 U.S. hemophiliacs alone exposed to via such concentrates between 1979 and 1985. In regions like the , Cutter's accounted for a portion of the 1,250+ hemophiliacs infected with , underscoring how production reliance on pooled, unscreened plasma—without robust inactivation—created a causal pathway for iatrogenic epidemics. This episode highlighted the plasma process's fragility to emerging blood-borne threats, where donor diversity and volume inherently outpaced early detection capabilities. In the mid-1980s, Cutter Laboratories, a division of following its acquisition through , faced scrutiny for distributing non-heat-treated concentrate—a blood clotting product used by hemophiliacs—despite emerging evidence of its contamination with . By early 1984, internal testing and epidemiological data linked the product to AIDS transmission among U.S. hemophiliacs, prompting Cutter to develop and prioritize heat-treated versions that inactivated the virus for the domestic market. However, company executives elected to offload remaining inventory of the untreated, high-risk product to overseas markets in and , including Taiwan, Hong Kong, Indonesia, and Malaysia, rather than destroy it, citing economic considerations to avoid losses estimated in the millions. This practice, documented in internal memos uncovered in 2003, exposed hemophiliacs in these regions to known risks, resulting in over 100 confirmed infections in and alone from Cutter's untreated between 1985 and 1986. Ethically, the decision has been condemned as a violation of core medical principles, including non-maleficence, by knowingly prioritizing inventory clearance and revenue recovery over , particularly in markets with limited regulatory oversight and access to alternatives. Critics, drawing from the revealed correspondence, argue it exemplified corporate opportunism, treating hemophiliacs in developing countries as expendable to safeguard U.S. market transitions, though contended that transmission risks were not conclusively established until later and that sales complied with local approvals. Legally, the episode triggered multiple class-action suits against Bayer's Cutter division, with hemophiliacs and estates in affected countries alleging , to warn, and intentional . In the U.S., where pre-1985 exposures from similar untreated products infected thousands, Bayer joined other manufacturers in a 1997 settlement totaling $600 million to compensate approximately 6,000 HIV-positive hemophiliacs, averting trials on liability for inadequate screening and processing. Overseas claims faced jurisdictional hurdles but led to further settlements and ongoing litigation; for instance, Taiwanese plaintiffs filed suits in 2003 seeking damages for infections traced to Cutter's exports, resulting in compensatory awards in select cases after Bayer acknowledged inventory sales but denied causation or foreknowledge of specific harms. These outcomes underscored tensions between doctrines and exemptions, with courts often applying strict standards for proving willful endangerment amid evolving on .

Legacy and Broader Impact

Contributions to Vaccine Technology

Cutter Laboratories pioneered the commercial production of a modified live virus against hog cholera () using techniques, with the first such vaccine released in 1952–1953. This represented an early advancement in cell culture-based vaccine manufacturing, shifting from traditional animal methods to more controlled, scalable processes that minimized variability and enhanced production efficiency for veterinary biologics. The approach involved propagating attenuated virus strains in porcine kidney cell cultures, demonstrating the feasibility of for generating immunogenic viral material without live animal passage, which laid groundwork for broader adoption in vaccine development. In human vaccine technology, Cutter contributed to the implementation of large-scale production for Jonas Salk's inactivated poliomyelitis vaccine, licensed on April 12, 1955. The process entailed growing types 1, 2, and 3 in primary rhesus monkey kidney cell cultures, followed by inactivation with to preserve while eliminating . As one of five U.S. manufacturers authorized by the Public Health Service, Cutter's facilities helped validate the practicality of propagation for human vaccines, enabling the rapid scaling to millions of doses required for nationwide immunization efforts. This methodology, refined through pre-licensure testing, marked a technological leap from earlier empirical vaccine strategies, emphasizing standardized cell substrate use and chemical inactivation for safety and potency. These efforts underscored Cutter's role in transitioning vaccine production toward modern biotechnological principles, including rigorous potency assays and serial manufacturing under controlled conditions. Although subsequent events revealed gaps in inactivation validation specific to Cutter's batches, the firm's pre-1955 innovations in application influenced the evolution of both veterinary and human platforms, contributing to the eventual eradication of hog cholera in the U.S. by 1978 and the near-global control of .

Influence on Public Health Policy and Debates

The Cutter Incident of 1955, in which polio vaccines produced by Cutter Laboratories contained residual live , affected approximately 40,000 individuals with polio infections, including 204 cases of paralytic and 11 deaths, directly prompting U.S. Leonard Scheele to suspend the national program on April 27, 1955. An emergency investigative panel convened by the and Service identified failures in the inactivation process and insufficient safety testing, leading to immediate federal mandates for enhanced pre-release protocols, such as multiple animal tests to detect live and stricter potency assays. These reforms expanded the authority of the National Institutes of Health's Division of Biologics Standards, institutionalizing independent oversight of manufacturing to prevent recurrence of production errors. The incident catalyzed a in regulation, emphasizing empirical validation of safety over expedited licensing amid urgency, as evidenced by the revised protocols that required field trials and lot-by-lot before distribution. It highlighted systemic vulnerabilities in relying on manufacturer self-testing, influencing the 1972 transfer of biologics licensing to the FDA and the establishment of Good Practices tailored for vaccines. Long-term, these changes informed global standards, including WHO guidelines on inactivated vaccines, by prioritizing causal mechanisms of failure—like incomplete neutralization—over procedural compliance alone. In legal spheres, the Gottsdanker v. Cutter Laboratories (1959) ruling imposed on manufacturers for defective products, rejecting Cutter's defense of adherence to federal specifications and affirming that government approval does not absolve responsibility for foreseeable harms. This doctrine fueled debates on incentivizing innovation versus ensuring accountability, as excessive litigation risks threatened vaccine supply; it directly contributed to the 1986 , which created a no-fault compensation fund to shield manufacturers from suits for unavoidable side effects, thereby stabilizing production amid rising liability costs. Critics, including affected families, argued the Act prioritized industry protection over victim recourse, while proponents cited it as essential for maintaining programs. The Cutter episode persists in debates as a benchmark for , invoked to critique accelerated approvals—such as during the 1976 swine flu campaign—and to advocate for transparent systems that detect rare adverse events post-licensure. It has informed discussions on empirical requirements, underscoring how overlooked variances can undermine trust, with analyses attributing the failure to inadequate process controls rather than inherent flaws. In contemporary contexts, it exemplifies the tension between rapid deployment for control and rigorous causal scrutiny, influencing policy resistance to liability waivers and calls for diversified production to mitigate single-firm failures.

References

  1. https://www.sciencedirect.com/science/article/pii/S0264410X2030668X
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC1383764/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC1410842/
  4. https://www.cdc.gov/vaccine-safety/historical-concerns/index.html
  5. https://www.fda.gov/about-fda/histories-product-regulation/science-and-regulation-biological-products
  6. https://openyls.law.yale.edu/bitstreams/a8632b30-7ddd-4bbb-8d91-afbdd41f2281/download
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7294234/
  8. https://baynature.org/2021/05/04/the-history-of-vaccines-through-an-east-bay-regional-park/
  9. https://berkhistory.org/wp-content/uploads/2022/02/2005_winter_newsletter.pdf
  10. https://data.isiscb.org/isis/authority/CBA000117908/
  11. https://cdnc.ucr.edu/?a=d&d=AL19080702.2.60
  12. https://americanhistory.si.edu/collections/object/nmah_1142733
  13. https://americanhistory.si.edu/collections/object/nmah_1142731
  14. https://americanhistory.si.edu/collections/object/nmah_1142735
  15. https://dokumen.pub/the-cutter-incident-how-americas-first-polio-vaccine-led-to-the-growing-vaccine-crisis-1nbsped-0300108648.html
  16. https://www.sfgate.com/sfhistory/article/polio-vaccine-cutter-laboratories-berkeley-15961438.php
  17. https://archives.boulderweekly.com/opinion/the-cutter-incident-a-cautionary-tale-for-operation-warp-speed/
  18. https://www.federalregister.gov/documents/2004/01/05/03-32255/biological-products-bacterial-vaccines-and-toxoids-implementation-of-efficacy-review
  19. https://www.cdc.gov/mmwr/preview/mmwrhtml/00056803.htm
  20. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html
  21. https://www.marchofdimes.org/about-us/mission/history/history-march-dimes
  22. https://files.eric.ed.gov/fulltext/EJ978264.pdf
  23. https://polioeradication.org/about-polio/history-of-polio/
  24. https://historyofvaccines.org/history/jonas-salk-md/timeline/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC1114166/
  26. https://sph.umich.edu/polio/
  27. https://www.salk.edu/news-release/the-day-polio-met-its-match-celebrating-70-years-of-the-salk-vaccine/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC2537626/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3782271/
  30. https://www.nytimes.com/1955/08/28/archives/science-in-review-cutter-polio-vaccine-report-highlights.html
  31. https://www.eisenhowerlibrary.gov/research/online-documents/jonas-salk-and-polio-vaccine
  32. https://www.immunize.org/vaccines/vaccine-timeline/
  33. https://stacks.cdc.gov/view/cdc/48111/cdc_48111_DS1.pdf
  34. https://historyofvaccines.org/blog/historical-vaccine-associated-incidents/
  35. https://www.newspapers.com/article/spokane-chronicle-cutter-laboratories-se/35575116/?locale=en-US
  36. https://historyofvaccines.org/vaccines-101/ethical-issues-and-vaccines/vaccine-injury-compensation-programs/
  37. https://law.justia.com/cases/california/court-of-appeal/2d/182/602.html
  38. https://www.jublhs.com/company/history/
  39. https://americanhistory.si.edu/collections/object-groups/antibody-initiative/veterinary?page=1
  40. https://collections.mdhs.unimelb.edu.au/objects/36990/cutter-hospital-products
  41. https://www.companieshistory.com/bayer-ag/
  42. https://www.bayer.com/en/history/1974-1988
  43. https://www.nytimes.com/1983/03/29/business/business-people-ex-bayer-division-head-takes-top-miles-posts.html
  44. https://www.fundinguniverse.com/company-histories/miles-laboratories-history/
  45. https://pubs.acs.org/doi/10.1021/cen-v055n040.p006a
  46. https://www.nytimes.com/1979/08/17/archives/company-news-bayer-of-germany-told-to-sell-some-us-units-talks-on.html
  47. https://lafayettehistory.org/oral-history-dave-cutter-december-2005/
  48. https://www.grifols.com/documents/6155538/6464490/np-20240418-en.pdf/d84216f3-a65b-6b3d-98ce-1b2d04c62ec8?t=1713436815348
  49. https://www.theguardian.com/world/2003/may/23/aids.suzannegoldenberg
  50. https://pubmed.ncbi.nlm.nih.gov/24785997/
  51. https://www.cdc.gov/mmwr/preview/mmwrhtml/00000421.htm
  52. https://law.justia.com/cases/federal/appellate-courts/F3/484/951/580455/
  53. https://www.theguardian.com/uk-news/2024/apr/27/plasma-true-story-uk-infected-blood-scandal-products
  54. https://www.industrydocuments.ucsf.edu/drug/collections/blood-products-litigation-documents
  55. https://www.telegraph.co.uk/news/2024/05/12/infected-blood-companys-cost-cutting-caused-polio-epidemic/
  56. https://www.infectedbloodinquiry.org.uk/sites/default/files/002-300%2520copy%25201/002-300%2520copy%25201/WITN0838028%2520-%25202%2520paths%2520of%2520Bayer%2520drug%2520in%252080s%2520Riskier%2520one%2520steered%2520overseas%2520-%252022%2520May%25202003.pdf
  57. https://kffhealthnews.org/morning-breakout/dr00029600/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC1151015/
  59. https://www.nejm.org/doi/full/10.1056/NEJMp048180
  60. https://www.aai.org/About/History/History-Articles-Keep-for-Hierarchy/Polio-Part-III%25E2%2580%2594The-Vaccine
  61. https://www.nber.org/programs-projects/projects-and-centers/8047-cutter-incident-consequences-public-health-crisis
  62. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-95362012000200003
  63. https://scholarship.law.vanderbilt.edu/cgi/viewcontent.cgi?article=3131&context=vlr
  64. https://www.ncbi.nlm.nih.gov/books/NBK216813/
  65. https://www.jstor.org/stable/j.ctt1njkt9
  66. https://www.statnews.com/2025/01/15/polio-vaccine-cutter-incident-rfk-jr-trump/
Add your contribution
Related Hubs
User Avatar
No comments yet.